The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | The VERIFY trial: rusfertide in patients with polycythemia vera
Aniket Bankar, MD, DM, MBBS, MSc, Princess Margaret Cancer Center, Toronto, Canada, introduces the VERIFY trial (NCT05210790), a randomized controlled Phase III study of the hepcidin mimetic rusfertide in patients with polycythemia vera (PV). The primary endpoint of the trial is achieving phlebotomy-independence, which is currently an unmet need in PV. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
